Health care industry
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz. U.S. Department of Health and Human Services President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency. Schwartz will have to be confirmed by the Senate, […]
Read More
Here’s our monthly update on all 31 portfolio stocks, including 3 on the buy list
The CNBC Investing Club held its April Monthly Meeting on Thursday, with Jim Cramer and Jeff Marks, director of portfolio analysis, hashing it out on each stock in the portfolio. The confab came a day after the S & P 500 closed at its first record high since late January, punctuating its dramatic comeback from […]
Read More
RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Piotr Swat | Lightrocket | Getty Images As its high-margin compounded GLP-1 business evolves, Hims & Hers Health may be finding a new opportunity in peptides. Shares of the telehealth company jumped Thursday after HHS Secretary Robert F. Kennedy Jr. announced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to […]
Read More
J&J tops first-quarter profit estimates even as Stelara sales plunge
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. And the company expressed confidence in its just-approved once-daily, oral psoriasis treatment, Icotyde, saying about 1,500 […]
Read More
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday. The partnership will enable Novo to better […]
Read More
Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all […]
Read More
Trump policies, China’s biotech boom are ending Europe’s pharma powerhouse era
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing […]
Read More
Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest […]
Read More
Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurers
Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks during an event sponsored by the Action for Progress Coalition, at the National Press Club in Washington, D.C., U.S., Feb. 2, 2026. Al Drago | Reuters The Trump administration on Monday finalized a 2027 payment rate increase to privately run Medicare plans that […]
Read More
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Piotr Swiat | Lightrocket | Getty Images Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker’s expansion into metabolic disorders. The deal gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, […]
Read More